The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma

Nicola Silvestris; Stefania Tommasi; Daniela Petriella; Daniele Santini; Ettore Fistola; Antonio Russo; Gianmauro Numico; Giuseppe Tonini; Evaristo Maiello; Giuseppe Colucci

doi:10.1159/000258498

The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma

Nicola Silvestris, Stefania Tommasi, Daniela Petriella, Daniele Santini, Ettore Fistola, Antonio Russo, Gianmauro Numico, Giuseppe Tonini, Evaristo Maiello, Giuseppe Colucci

Research output: Contribution to journal › Article

Abstract

Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR pathway as potential targeted anticancer drugs is encouraging, but this attractive therapy option is still at an early stage of development.

Original language	English
Pages (from-to)	69-74
Number of pages	6
Journal	Oncology
Volume	77
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1159/000258498
Publication status	Published - Feb 2010

Fingerprint

Keywords

AKT
Cetuximab
MTOR
Panitumumab
Phosphoinositide 3-kinases
PTEN

ASJC Scopus subject areas

Cancer Research
Oncology

Cite this

Silvestris, N., Tommasi, S., Petriella, D., Santini, D., Fistola, E., Russo, A., Numico, G., Tonini, G., Maiello, E., & Colucci, G. (2010). The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma. Oncology, 77(SUPPL. 1), 69-74. https://doi.org/10.1159/000258498

The dark side of the moon : The PI3K/PTEN/AKT pathway in colorectal carcinoma. / Silvestris, Nicola ; Tommasi, Stefania; Petriella, Daniela; Santini, Daniele; Fistola, Ettore; Russo, Antonio; Numico, Gianmauro; Tonini, Giuseppe; Maiello, Evaristo; Colucci, Giuseppe.

In: Oncology, Vol. 77, No. SUPPL. 1, 02.2010, p. 69-74.

Research output: Contribution to journal › Article

@article{18149fade9d44c7fbcf4798a15b97b3c,

title = "The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma",

abstract = "Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR pathway as potential targeted anticancer drugs is encouraging, but this attractive therapy option is still at an early stage of development.",

keywords = "AKT, Cetuximab, MTOR, Panitumumab, Phosphoinositide 3-kinases, PTEN",

author = "Nicola Silvestris and Stefania Tommasi and Daniela Petriella and Daniele Santini and Ettore Fistola and Antonio Russo and Gianmauro Numico and Giuseppe Tonini and Evaristo Maiello and Giuseppe Colucci",

year = "2010",

month = feb

doi = "10.1159/000258498",

language = "English",

volume = "77",

pages = "69--74",

journal = "Oncology",

issn = "0030-2414",

publisher = "UBM Medica Healthcare Publications",

number = "SUPPL. 1",

}

TY - JOUR

T1 - The dark side of the moon

T2 - The PI3K/PTEN/AKT pathway in colorectal carcinoma

AU - Silvestris, Nicola

AU - Tommasi, Stefania

AU - Petriella, Daniela

AU - Santini, Daniele

AU - Fistola, Ettore

AU - Russo, Antonio

AU - Numico, Gianmauro

AU - Tonini, Giuseppe

AU - Maiello, Evaristo

AU - Colucci, Giuseppe

PY - 2010/2

Y1 - 2010/2

N2 - Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR pathway as potential targeted anticancer drugs is encouraging, but this attractive therapy option is still at an early stage of development.

AB - Wild-type KRAS status is required but not sufficient to confer sensitivity to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in colorectal cancer patients. As a consequence, one of the major challenges is to identify, in non-mutant KRAS patients, other markers that can predict lack of response to this therapy. Small series have investigated the clinical effect of PIK3CA mutations on resistance to anti-EGFR mAbs and discrepant results have been observed. Furthermore, PTEN loss in metastases may be predictive of resistance to anti-EGFR mAbs, even if PTEN determination is far from an immediate clinical application. The introduction of modulators of the PI3K/AKT/mTOR pathway as potential targeted anticancer drugs is encouraging, but this attractive therapy option is still at an early stage of development.

KW - AKT

KW - Cetuximab

KW - MTOR

KW - Panitumumab

KW - Phosphoinositide 3-kinases

KW - PTEN

UR - http://www.scopus.com/inward/record.url?scp=77949888718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949888718&partnerID=8YFLogxK

U2 - 10.1159/000258498

DO - 10.1159/000258498

M3 - Article

C2 - 20130434

AN - SCOPUS:77949888718

VL - 77

SP - 69

EP - 74

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - SUPPL. 1

ER -

Access to Document

10.1159/000258498